Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RYZ101 in ER+/HER2- Advanced Breast Cancer
NCT06590857Phase 2Recruiting
- Sponsor
- RayzeBio
- Start
- Jul 2024
- Primary completion
- Oct 2028
- Modality
- Peptide-Drug Conjugates
- Countries
- 3
01
Overview
Phase 2, open-label trial of actinium-225 dotatate in breast cancer (2 arms), sponsored by RayzeBio. Primary endpoints: Dose Escalation at 6 weeks, Endocrine Therapy Combination Dose Escalation at 5 years and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06590857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590857.